Real-World Cardiovascular and Mortality Outcomes of Janus Kinase Inhibitors Versus Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2929; Pres time: Nov 11, 2026; 09:30 AM - 09:45 AM; Location: W414; In Person; "TNF inhibitors comprised adalimumab, etanercept, infliximab, certolizumab pegol, and golimumab. JAK inhibitors included tofacitinib, baricitinib, and upadacitinib... In this real-world study, Janus kinase inhibitors were associated with higher long-term mortality and a modest increase in major adverse cardiovascular events compared with tumor necrosis factor inhibitors, with notable differences across individual agents. These findings highlight the need for careful cardiovascular and thrombotic risk assessment when selecting JAK inhibitor therapy and support further prospective studies to refine patient selection."
Clinical • Real-world • Real-world evidence • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Venous Thromboembolism
|
|
Hanieh Akbari1; Shahrzad Abdollahi2
|